Ingenix, a healthcare AI startup founded in Poland by Piotr Surma and Adam Dancewicz, has raised €9 million in seed funding to accelerate development of its clinical trial simulation platform. The company is building a generative AI model capable of predicting trial outcomes — from molecular-level effects to population-wide responses — with the goal of reducing failure rates in drug development.
Surma said the platform could redefine the pharmaceutical industry’s approach to R&D, calling it “the sector’s GPT moment.” Backers include Inovo.vc, OTB Ventures, and the International Finance Corporation. Inovo’s Krzysztof Przybylak said the complexity of the challenge demands a rare caliber of team — one he believes Ingenix has.
Featured image: Credit: Piotr Surma and Adam Dancewicz
